{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:02:12Z","timestamp":1791943332261,"version":"4.3.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.biomaterials.2011.02.059","type":"journal-article","created":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T04:41:32Z","timestamp":1304224892000},"page":"4450-4463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances"],"prefix":"10.1016","volume":"32","author":[{"given":"Ehud","family":"Segal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaizhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Benayoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavla","family":"Kope\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Shaked","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jind\u0159ich","family":"Kope\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Satchi-Fainaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2011.02.059_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dna.2006.0505","article-title":"Molecular pathogenesis of osteosarcoma","volume":"26","author":"Kansara","year":"2007","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/cncr.22455","article-title":"Markers of angiogenesis and clinical features in patients with sarcoma","volume":"109","author":"DuBois","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib3","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1200\/JCO.2008.17.1108","article-title":"Osteosarcoma: the same old drugs or more?","volume":"26","author":"Bielack","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.biomaterials.2011.02.059_bib4","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1007\/BF01673412","article-title":"Role of cytokines in the regulation of bone resorption","volume":"53","author":"Roodman","year":"1993","journal-title":"Calcif Tissue Int"},{"issue":"Suppl. 1","key":"10.1016\/j.biomaterials.2011.02.059_bib5","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3816\/CBC.2007.s.001","article-title":"Biology of bone metastases: causes and consequences","volume":"7","author":"Harvey","year":"2007","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.med.50.1.237","article-title":"Bisphosphonates in the treatment of malignant bone disease","volume":"50","author":"Berenson","year":"1999","journal-title":"Annu Rev Med"},{"issue":"Suppl. 1","key":"10.1016\/j.biomaterials.2011.02.059_bib7","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ctrv.2008.03.008","article-title":"Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone","volume":"34","author":"Lipton","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1297-319X(01)00336-0","article-title":"Bisphosphonates in bone diseases other than osteoporosis","volume":"69","author":"Orcel","year":"2002","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/S1053-4296(00)80042-9","article-title":"The role of bisphosphonates in metastatic breast cancer","volume":"10","author":"Hillner","year":"2000","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib10","first-page":"505","article-title":"Osteoporosis, fracture risk, and prosthodontic implications","volume":"22","author":"Koka","year":"2009","journal-title":"Int J Prosthodont"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrrheum.2010.167","article-title":"Therapy: bisphosphonate users: cancer risk","volume":"6","author":"Leah","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10555-006-9031-1","article-title":"Anti-angiogenic therapy for osteosarcoma","volume":"25","author":"Quan","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib14","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0959-8049(99)00073-8","article-title":"Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma","volume":"35","author":"Lee","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1302\/0301-620X.91B6.21853","article-title":"The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma","volume":"91","author":"Kaya","year":"2009","journal-title":"J\u00a0Bone Joint Surg Br."},{"key":"10.1016\/j.biomaterials.2011.02.059_bib16","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1600-0463.2004.apm11207-0809.x","article-title":"Endogenous angiogenesis inhibitors","volume":"112","author":"Folkman","year":"2004","journal-title":"APMIS"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.57.121304.131306","article-title":"Angiogenesis","volume":"57","author":"Folkman","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00062752-200209000-00003","article-title":"Tissue factor and angiogenesis in cancer","volume":"9","author":"Fernandez","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nm1002","article-title":"Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470","volume":"10","author":"Satchi-Fainaro","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00280-010-1467-x","article-title":"Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer","volume":"66","author":"Egerton","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib23","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib24","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdp368","article-title":"Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy","volume":"20","author":"Wong","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib25","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/anie.200502113","article-title":"Polymer therapeutics: concepts and applications","volume":"45","author":"Haag","year":"2006","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib26","series-title":"Angiogenesis: an integrative approach from science to medicine","first-page":"387","article-title":"TNP-470: the resurrection of the first synthetic angiogenesis inhibitor","author":"Satchi-Fainaro","year":"2008"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/348555a0","article-title":"Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth","volume":"348","author":"Ingber","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib28","first-page":"1989","article-title":"A\u00a0phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer","volume":"5","author":"Bhargava","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib29","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1517\/13543784.9.6.1383","article-title":"TNP-470: an angiogenesis inhibitor in clinical development for cancer","volume":"9","author":"Kruger","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ccr.2005.02.007","article-title":"Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin","volume":"7","author":"Satchi-Fainaro","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib31","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1021\/bm049825h","article-title":"Facile, controlled, room-temperature RAFT polymerization of N-isopropylacrylamide","volume":"5","author":"Convertine","year":"2004","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib32","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.addr.2009.06.005","article-title":"Design and development of polymer conjugates as anti-angiogenic agents","volume":"61","author":"Segal","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1021\/bc034090j","article-title":"Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems","volume":"14","author":"Wang","year":"2003","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib34","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1021\/mp800003u","article-title":"Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates","volume":"5","author":"Pan","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib35","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1021\/bc7002132","article-title":"Osteotropic peptide that differentiates functional domains of the skeleton","volume":"18","author":"Wang","year":"2007","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mc.20362","article-title":"Cathepsins and osteosarcoma: expression analysis identifies cathepsin K as an indicator of metastasis","volume":"47","author":"Husmann","year":"2008","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/10611860600834219","article-title":"Water-soluble HPMA copolymer\u2013prostaglandin E1 conjugates containing a cathepsin K sensitive spacer","volume":"14","author":"Pan","year":"2006","journal-title":"J\u00a0Drug Target"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib38","doi-asserted-by":"crossref","first-page":"e5233","DOI":"10.1371\/journal.pone.0005233","article-title":"Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics","volume":"4","author":"Segal","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib39","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2353\/ajpath.2007.060929","article-title":"Murine models to evaluate novel and conventional therapeutic strategies for cancer","volume":"170","author":"Talmadge","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0959-8049(99)00241-5","article-title":"The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease","volume":"36","author":"O\u2019Byrne","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib41","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1158\/1078-0432.CCR-06-0329","article-title":"Barriers to efficient development of cancer therapeutics","volume":"12","author":"Schein","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis","volume":"114","author":"Giraudo","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/A:1006767007547","article-title":"An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential","volume":"18","author":"Khanna","year":"2000","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib44","first-page":"27","article-title":"The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer","volume":"1796","author":"Bertolini","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2174\/156800905774574020","article-title":"Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose","volume":"5","author":"Shaked","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib46","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1126\/science.1127592","article-title":"Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors","volume":"313","author":"Shaked","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib47","first-page":"101","article-title":"Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis","volume":"7","author":"Shaked","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib48","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2005-11-4570","article-title":"Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy","volume":"108","author":"Mancuso","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-3659(97)00235-6","article-title":"Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate","volume":"53","author":"Omelyanenko","year":"1998","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib50","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0731-7085(02)00021-3","article-title":"Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions","volume":"28","author":"Kuljanin","year":"2002","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib51","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/0008-5472.540.65.2","article-title":"Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model","volume":"65","author":"Hashimoto","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/10611869409015915","article-title":"A\u00a0polymer-Triton X-100 conjugate capable of PH-dependent red blood cell lysis: a model system illustrating the possibility of drug delivery within acidic intracellular compartments","volume":"2","author":"Duncan","year":"1994","journal-title":"J\u00a0Drug Target"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib53","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1089\/jpm.2009.9936","article-title":"Toxicity of bisphosphonates","volume":"12","author":"Prommer","year":"2009","journal-title":"J\u00a0Palliat Med"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib54","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s002239900535","article-title":"The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells","volume":"63","author":"Pietschmann","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib55","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","article-title":"Chemotherapy-induced anemia in adults: incidence and treatment","volume":"91","author":"Groopman","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib56","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","article-title":"Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer","volume":"26","author":"Dellapasqua","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ccr.2004.12.014","article-title":"A\u00a0surrogate marker to monitor angiogenesis at last","volume":"7","author":"Schneider","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib58","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1191\/096032701682693017","article-title":"Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent","volume":"20","author":"Hopewel","year":"2001","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib59","doi-asserted-by":"crossref","first-page":"e9536","DOI":"10.1371\/journal.pone.0009536","article-title":"Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method","volume":"5","author":"Lee","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib60","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/bbrc.1995.1013","article-title":"Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone","volume":"206","author":"Inaoka","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib61","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2009.10.004","article-title":"HPMA copolymers: origins, early developments, present, and future","volume":"62","author":"Kopecek","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1677\/erc.1.01094","article-title":"Emerging anti-cancer molecular mechanisms of aminobisphosphonates","volume":"13","author":"Caraglia","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib63","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.addr.2004.12.015","article-title":"Designing proteins for bone targeting","volume":"57","author":"Gittens","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib64","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/app.23446","article-title":"Hydroxybisphosphonate-containing polymeric drug-delivery systems designed for targeting into bone tissue","volume":"101","author":"Hrub\u00fd","year":"2006","journal-title":"J\u00a0Appl Polym Sci"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib65","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/anie.200805133","article-title":"Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate\u2013taxane conjugate","volume":"48","author":"Miller","year":"2009","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib66","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drup.2009.12.001","article-title":"Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy","volume":"13","author":"Abdollahi","year":"2010","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib67","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s11095-008-9706-0","article-title":"Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats","volume":"25","author":"Miller","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib68","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1023\/B:PHAM.0000045232.18134.e9","article-title":"The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study","volume":"21","author":"Wang","year":"2004","journal-title":"Pharm Res"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib69","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1083\/jcb.200910104","article-title":"Targeting of drugs and nanoparticles to tumors","volume":"188","author":"Ruoslahti","year":"2010","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib70","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1958","article-title":"Polymer conjugates as anticancer nanomedicines","volume":"6","author":"Duncan","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib71","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1158\/0008-5472.CAN-10-0460","article-title":"Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis","volume":"70","author":"Iadevaia","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib72","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0142-9612(89)90075-6","article-title":"Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro","volume":"10","author":"Rihova","year":"1989","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib73","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/8756-3282(95)00400-9","article-title":"Sustained response to intravenous alendronate in postmenopausal osteoporosis","volume":"17","author":"Vasikaran","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib74","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1039\/B919329D","article-title":"Real-time monitoring of drug release","volume":"46","author":"Weinstain","year":"2010","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib75","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1158\/1535-7163.MCT-07-0546","article-title":"Zoledronic acid inhibits osteosarcoma growth in an orthotopic model","volume":"6","author":"Dass","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.coi.2004.01.003","article-title":"Animal models of tumor immunity, immunotherapy and cancer vaccines","volume":"16","author":"Ostrand-Rosenberg","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib77","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1242\/dmm.000976","article-title":"Mouse xenograft models vs GEM models for human cancer therapeutics","volume":"1","author":"Richmond","year":"2008","journal-title":"Dis Models Mech"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib78","first-page":"3964","article-title":"Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes","volume":"53","author":"Williams","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.biomaterials.2011.02.059_bib79","first-page":"300","article-title":"Primer for non-immunologists on immune-deficient mice and their applications in research","volume":"51","author":"Croy","year":"2001","journal-title":"Comp Med"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961211002365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961211002365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:28:32Z","timestamp":1758900512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961211002365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":79,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0142961211002365"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2011.02.059","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2011.02.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}